JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk
Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers
Abstract
<b>JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19.</b>https://bit.ly/2NQ15K5
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Vigilance (psychology)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicinePandemicIntensive care medicineVirologyInternal medicineBiologyOutbreakInfectious disease (medical specialty)DiseaseNeuroscienceMyeloproliferative Neoplasms: Diagnosis and TreatmentInflammasome and immune disordersCytokine Signaling Pathways and Interactions